Immutep completes enrolment in Phase 2 trial of AIPAC-003 in breast cancer

Immutep announced patient enrolment has been completed in the randomised Phase II portion of the AIPAC-003 clinical trial. The Phase II enrolled 65 metastatic breast cancer patients who exhausted endocrine therapy. Patients across 22 clinical sites in Europe and the U.S. have been randomised 1:1 to receive eftilagimod alpha in combination with paclitaxel to determine the optimal biological dose consistent with the FDA’s Project Optimus initiative.